본문 바로가기 주메뉴 바로가기
국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

초록보기

Background Fatigue significantly affects health-related quality of life (HRQoL) in patients with immune thrombocytopenia (ITP). However, the interplay between fatigue and cytokines in ITP remains poorly understood.

Methods This study included 100 patients with persistent or chronic ITP who had not received ITP-directed therapy in the previous 8 weeks and 50 age-matched healthy controls. Fatigue and HRQoL were assessed using the Functional Assessment of the Chronic Illness Therapy (FACIT) scale. Concurrently, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, IL-17, and interferon-gamma (IFN-γ) were measured via enzyme-linked immunosorbent assay (ELISA).

Results ITP patients had significantly lower total FACIT scores [median 146 (range 59–160]) and fatigue subscale scores [median 45 (range 9–52]) than controls [155 (149–159) and 49 (44–52), respectively; both p < 0.001]. IL-12 levels were significantly elevated in patients (313.2 vs. 95.5 pg/mL; p < 0.001) and showed a significant negative correlation with FACIT scores (Spearman’s ρ = –0.272, p = 0.007). Multivariate analysis revealed that female sex, longer disease duration among patients with chronic ITP (> 24 months), and elevated IL-12 levels were independently associated with greater fatigue and poorer HRQoL.

Conclusions ITP is associated with significant fatigue and HRQoL impairment, with IL-12 emerging as a potential immunological marker linked to this symptom burden.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Molecular spectrum and carrier frequency of deletional hereditary persistence of fetal hemoglobin and delta-beta thalassemia in Malaysia Faidatul Syazlin Abdul Hamid, Sabariah Md Noor, Mei I Lai, Samsol Kamal Mohd Bahari, Ezalia Esa, Ermi Neiza Mohd Sahid, Norafiza Mohd Yasin, Yuslina Mat Yusoff p. 1-8
Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes Junshik Hong p. 1-7
Treatment of transplant-ineligible multiple myeloma Jongheon Jung p. 1-7
Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease : an explorative study Sieun Oh, Sung-Soo Park, Jung Yeon Lee, Jae-Ho Yoon, Sung-Eun Lee, Hee-Je Kim, Seung-Hwan Shin, Young-Woo Jeon, Seung-Ah Yahng, Jin Jung, Ari Ahn, Myungshin Kim, Chang-Ki Min p. 1-10
Aggressive natural killer cell leukemia therapy in the L-asparaginase era : why are we failing? Sang Eun Yoon, Junhun Cho, Hyun-Young Kim, Seok Jin Kim, Won Seog Kim p. 1-13
Unveiling the role of microRNAs, the PI3K/AKT pathway, and their associations in various types of leukemia : a comprehensive review Amir Modarresi Chahardehi, Esfandiar Mali, Arya Afrooghe, Amirmasoud Asadi, Amirreza Khalaji, Hamed Soleimani Samarkhazan, Hananeh Esmaeil Beygi, Amirhossein Mohagheghi, Maryam Khanbabaei, Heliya Haghani, Reza Arefnezhad, Fatemeh Rezaei-Tazangi p. 1-13
Early CD4 + T cell immune reconstitution as a biomarker for Epstein-Barr virus control following allogeneic transplantation Kexin Lin, Wenwen Yang, Jiaxiu Yin, Jing Luo, Hao Zhou, Lanxiang Liu, Li Yang, Jie Luo, Lin Liu, Junli Mou p. 1-10
Beyond anemia : unraveling neutrophil defects and infection susceptibility in β-Thalassemia Chingiz Asadov, Gunay Aliyeva p. 1-10
(Correspondence) Durable responses and favorable cost-effectiveness of rituximab‑based chemoimmunotherapy for primary cold agglutinin disease Kenichi Ito, Tomoko Kitagawa, Saya Motohashi, Kazuhiko Hirano, Naohiro Sekiguchi p. 1-6
(Correspondence) Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma : bispecific antibodies and CAR T-Cell therapies So Yeon Park, Gi-June Min p. 1-6
(A) comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera : a real-world data-based analysis Sung-Eun Lee, Seug Yun Yoon, Sung-Yong Kim, Soo-Mee Bang, Insoo Lee, Jihyuk Lee, Junshik Hong p. 1-7
Plasma interleukin‑12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia Sarthak Wadhera, Arihant Jain, Aarushi Sahni, Rudra Narayan Swain, Charanpreet Singh, Aditya Jandial, Ritu Aggarwal, Rekha Hans, Gaurav Prakash, Alka Khadwal, Sandeep Grover, Reena Das, Pankaj Malhotra p. 1-8
Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant‑eligible Korean patients with relapsed or refractory Hodgkin’s lymphoma Jun Ho Yi, Young Hoon Park, Myungwon Lee, Kwai Han Yoo, Junshik Hong, HyeonSeok Eom p. 1-6
Insights into treatment‑free remission (TFR) outcomes in chronic myeloid leukaemia (CML) : a tertiary centre experience in Malaysia Christopher Chin Keong Liam, Yang Liang Boo, Li Min Lim, Siew Lian Chong, Azizan Sharif, Yih Seong Wong, Veena Selvaratnam, Sen Mui Tan, Soo Min Lim p. 1-7
Invasive fungal infections in hematologic diseases : evidence, challenges, and clinical practice SungYeon Cho, Chae Eun Lee, Dukhee Nho, DongGun Lee p. 1-7
(Correspondence) Measurable residual disease monitoring after hematopoietic stem cell transplantation Saeam Shin p. 1-3
(Correspondence) Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches Keli Lima, Frederico Lisboa Nogueira, Catarina Sofia Mateus Reis‑Silva, Rita de Cássia Cavaglieri, Leticia Veras Costa‑Lotufo, João Agostinho Machado‑Neto, Eduardo Magalhães Rego p. 1-5